Please ensure Javascript is enabled for purposes of website accessibility

Why Bausch Health Companies Stock Sank Today

By Keith Speights - Oct 1, 2019 at 3:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A lawsuit over the company's top-selling drug caused investors to worry.

What happened

Shares of Bausch Health Companies (BHC 4.49%) were sinking by 8.6% as of 2:51 p.m. EDT on Tuesday. The decline came after Bausch Health announced that it had filed a lawsuit against Novartis (NVS -0.35%) subsidiary Sandoz, related to alleged infringement of patents for diarrhea drug Xifaxan.

So what

Bausch Health's lawsuit was a reaction to Sandoz's filing of an Abbreviated New Drug Application (ANDA), in hopes of receiving approval to market a generic version of Xifaxan 550 mg tablets. Bausch Health maintains that this ANDA filing infringes on 14 patents for Xifaxan.

Hand holding a pen over a document reading Notice of a Lawsuit

Image source: Getty Images.

The need for litigation highlighted the risk for Bausch Health. Xifaxan is a primary source of revenue growth for the company, with sales for the drug jumping 21% year over year in the second quarter. It currently contributes over 16% of Bausch Health's total revenue. If a generic version of Xifaxan reached the market, it would seriously threaten Bausch Health's growth prospects.

Bausch Health stated that it "remains confident in the strength of the Xifaxan patents and will continue to vigorously defend its intellectual property." The company has 22 patents in total for the drug, which cover composition of matter and use.

Now what

Patent litigation comes with the territory when investing in pharmaceutical stocks. In many cases, though, the disagreements are settled before the matter makes it to court.

For example, last year Bausch Health reached a settlement in a similar lawsuit with Actavis Laboratories, which is owned by Teva Pharmaceutical. Under the deal, Actavis will be able to market a generic version of Xifaxan 550 mg tablets in the U.S. beginning in 2028. If Bausch Health can strike a deal along these lines with Sandoz, today's drop should only be a temporary issue.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
BHC
$6.28 (4.49%) $0.27
Novartis AG Stock Quote
Novartis AG
NVS
$85.38 (-0.35%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.